Peter Fong

Partner, President

2023 - Current

Partner, Chief Development Officer

2022 - 2023

Senior Managing Director, Head of Asset Development and Financing

2021 - 2022

Senior Managing Director, Head of Company Creation

2019 - 2021

Board Executive Director

2019

Chief Executive Officer

2022 - 2022

Founding Chief Executive Officer

2019 - 2021

Senior Principal

2018 - 2019

Peter Fong joined Flagship Pioneering as Senior Principal on Flagship's innovation team in 2018 where he focused on company creation. His responsibilities included leading a team of Flagship entrepreneurial scientists to create first-in-category biotech companies.

iCEO, Harbinger Health

2018 - 2019

iCEO, FL66

2018 - 2019

iCEO, FL54

2018 - 2019

iCEO, FL60

2018 - 2019

Associate Director, Oncology Business Development, Genentech Partnering

2016 - 2018

Associate Director of Oncology Business Development in the Genentech Partnering Group in South San Francisco. Responsible for sourcing, screening, evaluating, and acquiring new therapeutics to build the company's oncology pipeline.

Senior Manager, Oncology Business Development, Genentech Partnering

2014 - 2016

New Ventures and Business Development

2009 - 2014

Launched and lead Memorial Sloan-Kettering Cancer Center’s (MSKCC’s) New Ventures and Business Development unit.

Co-Founder and VP of R&D

2007 - 2009

Co-invented novel nanoparticles for targeted drug delivery, and used technology to build oncology-based biotech company spun out of Yale University. Carigent's IP was licensed by Bind Therapeutics.

James Hudson Brown — Alexander Brown Coxe Postdoctoral Fellow

2003 - 2007

Nanoparticle drug delivery research for therapeutic applications and tissue engineering. Work resulted in more than 10 issued or pending patents, some of which have been licensed to 6 biotech or pharmaceutical companies, including Bind Therapeutics, Amgen, and Pfizer.

Graduate Student Research Assistant

1998 - 2003

Developed novel tissue-like biomaterials to study the effects of radiation in tissue for oncology radiotherapy applications. The central approach involved evaluating free-radical induced polymerization and its effect on NMR relaxation.

Chemist

1995 - 1998

Worked on the discovery and development of novel block co-polymers for high-heat applications.